Reimbursement of malaria chemoprophylaxis for travellers from Europe to Sub-Saharan Africa: Cost-effectiveness analysis from the perspective of the French national health insurance system

Health Policy

Volumn 88, Issue 2-3, 2008, Pages 186-199

  Pistone, Thierry ^a,b,c,d   Schwarzinger, Michaël ^a,b   Chauvin, Pierre ^a,b   Ezzedine, Khaled ^c   Receveur, Marie Catherine ^c,d   Djossou, Félix ^d   Siriwardana, Mahinda ^a,b   Larouzé, Bernard ^a,b   Malvy, Denis ^c,d  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Centre René Labusquière   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Africa; Chemoprophylaxis; Cost; Effectiveness; Health insurance; Malaria; Prophylaxis; Review; Travellers

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE PLUS PROGUANIL; DOXYCYCLINE; MEFLOQUINE;

AFRICA; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FRANCE; HEALTH INSURANCE; HUMAN; INCIDENCE; MALARIA; REIMBURSEMENT;

AFRICA SOUTH OF THE SAHARA; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; EUROPE; FEMALE; FRANCE; HUMANS; MALARIA; MALE; NATIONAL HEALTH PROGRAMS; REIMBURSEMENT MECHANISMS; TRAVEL;

EID: 56949104347     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2008.03.002     Document Type: Article

References (60)

1. DGAC: Direction Générale de l'aviation civile. Trafic des relations France - Pays étrangers année 2005 (Air traffic between France and foreign parts, 2005). France: http://www.aviation-civile.gouv.fr/html/prospace/stats/pdf_sdeep/bil2006/drebul3_2005.pdf [accessed June 2006].
2. CNREPIA: Centre National de Référence de l'Épidémiologie du Paludisme d'Importation et Autochtone France, http://www.med.univ-angers.fr/anofel/cnrepia.html [accessed March 2007].
3. Legros F, Arnaud A, El Mimouni B, Danis M. Paludisme d'importation en France métropolitaine: données épidémiologiques 2001-2004 (Malaria imported in France: epidemiological data 2001-2004), http://www.invs.sante.fr/beh/2006/32/beh_32_2006.pdf; 2006, BEH no. 32/2006, France [accessed March 2007].
4. Boutin J.P., Pradines B., Pages F., Legros F., Rogier C., and Migliani R. Epidemiology of malaria. La Revue du praticien 55 8 (2005) 833-840
5. Bouchaud O. Malaria: no shortage of patients but the market is failing. La Revue du praticien 55 8 (2005) 829-831
6. Danis M., Legros F., and Brousse G. Malaria chemoprophylaxis in 2005: new policy, new drugs. La Revue du praticien 55 8 (2005) 849-861
7. SPILF. Recommandations pour la pratique clinique de prise en charge et la prévention du paludisme d'importation à Plasmodium falciparum. Société de Pathologie Infectieusqe de langue Française: C., http://www.infectiologie.com; 2007 [accessed October 2007].
8. Badrinath P., Ejidokun O.O., Barnes N., and Ramaiah S. Change in NHS regulations may have caused increase in malaria. British Medical Journal 316 7146 (1998) 1746-1747
9. OTTI. 2002 Profile of US resident travelers visiting overseas destinations reported from: survey of international air travelers. Office of travel and tourism industries, US Department of Commerce, http://tinetitadocgov/cat/f-2002-101-001html; 2002 [accessed September 2007].
10. Behrens R.H. Visiting friends and relatives. In: Keystone J.S., Kozasky P.E., Freedman D.O., Northdurf H.D., and Conner B.A. (Eds). Travel medicine London (2004), Elsevier Ltd., England 281-285
11. McCarthy M. Should visits to relatives carry a health warning?. Lancet 357 9259 (2001) 862
12. INSEE. Enquêtes annuelles de recensement 2004 et 2005. Près de 5 millions d'immigrés à la mi-2004 (French yearly census 2004 and 2005; 5 millions of immigrants). Insee première no. 1098/2006, France, http://www.insee.fr/fr/ffc/ipweb/ip1098/ip1098.html; 2006 [accessed March 2007].
13. Pistone T., Guibert P., Gay F., Malvy D., Ezzedine K., Receveur M.C., et al. Malaria risk perception, knowledge and prophylaxis practices among travellers of African ethnicity living in Paris and visiting their country of origin in sub-Saharan Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene 101 10 (2007) 990-995
14. In VS. Santé des voyageurs et recommandations sanitaires françaises 2006 [Health recommendations for French travellers], in BEH no. 23-24/2006, France, http://www.invs.sante.fr/beh/2006/23_24/beh_23_24_2006.pdf; 2006 [accessed March 2007].
15. Allonier C, Dourgnon P, Rochereau T. Renoncement à des soins pour raisons financières (forgone healthcare because of financial matters). In: Allonier C, Dourgnon P, Rochereau T, editors. Santé, soins et protection sociale en 2004. Paris. IRDES 2006, série "résultats": 171-174.
16. In VS. Santé des voyageurs et recommandations sanitaires françaises 2007 [Health recommendations for French travellers], in BEH no. 24/2007, France, http://www.invs.sante.fr/beh/2007/24/beh_24_2007.pdf; 2007 [accessed June 2007].
17. Malvy D., Pistone T., Rezvani A., Lancon F., Vatan R., Receveur M.C., et al. Risk of malaria among French adult travellers. Travel Medicine and Infectious Disease 4 5 (2006) 259-269
18. Semaille C., Santin A., Prazuck T., Bargain P., Lafaix C., and Fisch A. Malaria chemoprophylaxis of 3,446 French travelers departing from Paris to eight tropical countries. Journal of Travel Medicine 6 1 (1999) 3-6
19. Laver S.M., Wetzels J., and Behrens R.H. Knowledge of malaria, risk perception, and compliance with prophylaxis and personal and environmental preventive measures in travelers exiting Zimbabwe from Harare and Victoria Falls International airport. Journal of Travel Medicine 8 6 (2001) 298-303
20. Van Herck K., Van Damme P., Castelli F., Zuckerman J., Nothdurft H., Dahlgren A.L., et al. Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. Journal of Travel Medicine 11 1 (2004) 3-8
21. Toovey S., Jamieson A., and Holloway M. Travelers' knowledge, attitudes and practices on the prevention of infectious diseases: results from a study at Johannesburg International Airport. Journal of Travel Medicine 11 1 (2004) 16-22
22. Waner S., Durrhiem D., Braack L.E., and Gammon S. Malaria protection measures used by in-flight travelers to South African game parks. Journal of Travel Medicine 6 4 (1999) 254-257
23. Gisler S., Steffen R., and Mutsch M. Knowledge, attitudes and practices among travellers to tropical and subtropical countries. Schweizerische Rundschau fur Medizin Praxis 94 23 (2005) 967-974
24. Lobel H.O., Baker M.A., Gras F.A., Stennies G.M., Meerburg P., Hiemstra E., et al. Use of malaria prevention measures by North American and European travelers to East Africa. Journal of Travel Medicine 8 4 (2001) 167-172
25. Hamer D.H., and Connor B.A. Travel health knowledge, attitudes and practices among United States travelers. Journal of Travel Medicine 11 1 (2004) 23-26
26. Leonard L., and VanLandingham M. Adherence to travel health guidelines: the experience of Nigerian immigrants in Houston, Texas. Journal of Immigrant Health 3 1 (2001) 31-45
27. Morgan M., and Figueroa-Munoz J.I. Barriers to uptake and adherence with malaria prophylaxis by the African community in London, England: focus group study. Ethnicity & Health 10 4 (2005) 355-372
28. Angell S.Y., and Behrens R.H. Risk assessment and disease prevention in travelers visiting friends and relatives. Infectious Disease Clinics of North America 19 1 (2005) 49-65
29. Schilthuis H.J., Goossens I., Ligthelm R.J., de Vlas S.J., Varkevisser C., and Richardus J.H. Factors determining use of pre-travel preventive health services by West African immigrants in The Netherlands. Tropical Medicine & International Health 12 8 (2007) 990-998
30. OCP. Amounts of each malaria chemoprophylaxis drug distributed by OCP to French pharmacies in 2006: OCP, sylvie.loison@ocp.fr; 2006 [contacted March 2007].
31. Steffen R., Heusser R., Machler R., Bruppacher R., Naef U., Chen D., et al. Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy. Bulletin of the World Health Organization 68 3 (1990) 313-322
32. Steffen R., Fuchs E., Schildknecht J., Naef U., Funk M., Schlagenhauf P., et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 341 8856 (1993) 1299-1303
33. Schlagenhauf P., Tschopp A., Johnson R., Nothdurft H.D., Beck B., Schwartz E., et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. British Medical Journal 327 7423 (2003) 1078
34. Moore D.A., Grant A.D., Armstrong M., Stumpfle R., and Behrens R.H. Risk factors for malaria in UK travellers. Transactions of the Royal Society of Tropical Medicine and Hygiene 98 1 (2004) 55-63
35. Fontanet A.L., Houze S., Keundjian A., Schiemann R., Ralaimazava P., Durand R., et al. Efficacy of antimalarial chemoprophylaxis among French residents travelling to Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene 99 2 (2005) 91-100
36. McKeage K., and Scott L. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria. Drugs 63 6 (2003) 597-623
37. Hogh B., Clarke P.D., Camus D., Nothdurft H.D., Overbosch D., Gunther M., et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. Lancet 356 9245 (2000) 1888-1894
38. Sarrouy J., Cellier C., Migliani R., Todesco A., Favier G., Linden L., et al. Chemoprophylaxis of Plasmodium falciparum malaria by a combination of 100 mg of chloroquine and 200 mg of proguanil per day in a zone III of chloroquine resistance (Gabon). Study of 431 French soldiers. Bulletin de la Societe de Pathologie Exotique 84 1 (1991) 80-93
39. Andersen S.L., Oloo A.J., Gordon D.M., Ragama O.B., Aleman G.M., Berman J.D., et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clinical Infectious Diseases 26 1 (1998) 146-150
40. Ohrt C., Richie T.L., Widjaja H., Shanks G.D., Fitriadi J., Fryauff D.J., et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 126 12 (1997) 963-972
41. Taylor W.R., Richie T.L., Fryauff D.J., Picarima H., Ohrt C., Tang D., et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clinical Infectious Diseases 28 1 (1999) 74-81
42. Baudon D., Martet G., Pascal B., Bernard J., Keundjian A., and Laroche R. Efficacy of daily antimalarial chemoprophylaxis in tropical Africa using either doxycycline or chloroquine-proguanil; a study conducted in 1996 in the French Army. Transactions of the Royal Society of Tropical Medicine and Hygiene 93 3 (1999) 302-303
43. Schlagenhauf P. Mefloquine for malaria chemoprophylaxis 1992-1998: a review. Journal of Travel Medicine 6 2 (1999) 122-133
44. Croft A.M., and Garner P. Mefloquine for preventing malaria in non-immune adult travellers. Cochrane Database of Systematic Reviews 4 (2000) CD000138
45. Hale B.R., Owusu-Agyei S., Fryauff D.J., Koram K.A., Adjuik M., Oduro A.R., et al. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clinical Infectious Diseases 36 5 (2003) 541-549
46. Overbosch D., Schilthuis H., Bienzle U., Behrens R.H., Kain K.C., Clarke P.D., et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clinical Infectious Diseases 33 7 (2001) 1015-1021
47. Ling J., Baird J.K., Fryauff D.J., Sismadi P., Bangs M.J., Lacy M., et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clinical Infectious Diseases 35 7 (2002) 825-833
48. Barrett P.J., Emmins P.D., Clarke P.D., and Bradley D.J. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. British Medical Journal 313 7056 (1996) 525-528
49. JO. Arrêté du 25 août 2006 modifiant l'arrêté du 5 mars 2006 relatif à la classification et à la prise en charge de prestations d'hospitalisation pour les activités de médecine, chirurgie, obstétrique et odontologie et pris en application de l'article L.162-22-6 du code de la sécurité sociale, http://www.atih.sante.fr. France: JO; August 30, 2006 [accessed October 2006].
50. ATIH. Statistiques PMSI par GHM codant Paludisme. Ensemble des bases nationales publiques et privée, année 2004. France: Agence Technique de l'information sur l'Hospitalisation 2006, http://stats.atih.sante.fr/mco/statone.php [accessed October 2006].
51. CNRMI. Impact économique du paludisme en France métropolitaine en 1996. Bulletin CNRMI 13 (1997) 46-48
52. CNAM. Prise en charge de la Caisse Nationale d'Assurance Maladie (CNAM): consultation, arrêt de travail pour maladie [Repayment by public French social insurance: medical visit and leave of absence from work], www.ameli.fr. France; 2006 [accessed December 2006].
53. Pistone T., Receveur M.C., Audo B., Ezzedine K., and Malvy D. Connaissance et perception des risques liés au voyage avant consultation au centre international de vaccination et de conseil au voyageur, CHU de Bordeaux (Knowledge and risks perception of international travellers before a travel clinic visit in the University Hospital Center of Bordeaux 2002). Proceeding of the Seventh Journées nationales d'infectiologie (JNI, French national meeting on infectiology). 2006 June 7-9, Bordeaux, France (2006)
54. Matsika-Claquin M.D., Menard D., Fontanet A.L., Ngwhotue A., Sarda J., and Talarmin A. Efficacy of chloroquine-proguanil malaria prophylaxis in a non-immune population in Bangui, Central African Republic: a case-control study. Transactions of the Royal Society of Tropical Medicine and Hygiene 100 4 (2006) 381-386
55. Behrens R.H., and Roberts J.A. Is travel prophylaxis worth while? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers. British Medical Journal 309 6959 (1994) 918-922
56. Dinkel R., Banz K., Buchner K., Steffen R., and Gutzwiller F. Cost-benefit analysis of malaria prophylaxis with mefloquine in travelers to Kenya. Sozial- und Praventivmedizin 35 6 (1990) 213-219
57. Bazin F., Parizot I., and Chauvin P. Original approach to the individual characteristics associated with forgone healthcare: a study in underprivileged areas, Paris region, France, 2001-2003. European Journal of Public Health 15 4 (2005) 361-367
58. Bacaner N., Stauffer B., Boulware D.R., Walker P.F., and Keystone J.S. Travel medicine considerations for North American immigrants visiting friends and relatives. The Journal of the American Medical Association 291 23 (2004) 2856-2864
59. JO. Arrêté du 29 janvier 2007 inscrivant Malarone et Lariam sur la liste des spécialités remboursables pour le traitement prophylactique du paludisme des sujets assurés sociaux de Guyane, www.legifrance.fr. France: JO; February 14, 2007 [accessed May 2007].
60. Loubiere S., Rotily M., Durand-Zaleski I., and Costagliola D. Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. Vox Sanguinis 80 4 (2001) 199-204